Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Genetic Testing Targets Risk Factor for Colon Cancer

By LabMedica International staff writers
Posted on 31 May 2011
A screening procedure has been developed that radically increases testing for Lynch syndrome, a hereditary genetic disorder that increases cancer risk. More...


Paraffin-embedded biopsies from cancerous tissue can be examined for certain mutations in genes that repair DNA by testing different DNA markers for irregularities.

Pathologists at the Mayo Clinic (Rochester, MN, USA) tested all resected newly diagnosed colorectal cancers in patients who were less than 51 years of age, from 2003 to 2008. All the patients automatically underwent polymerase chain reaction (PCR)-based microsatellite instability (MSI) testing if there was no testing prior to surgical resection. In MSI, DNA is isolated from normal and cancer tissue is then PCR-amplified across mononucleotide microsatellites and analyzed by fluorescent capillary electrophoresis. Allelic profiles from the normal and malignant tissue are compared to determine the MSI status which is reported as microsatellite instability high (MSI-H), an abnormal result, or microsatellite instability low or stable (MSI-L or MSS), both normal results. Patients with a history of inflammatory bowel disease or polyposis syndrome were excluded.

Over the five-year period, 210 of 258 newly diagnosed young patients undergoing surgery, 128 had preoperative and 82 postoperative testing. Of the 48 not tested, 29 eligible for postoperative reflex testing were missed, 15 had a complete pathological response after neoadjuvant therapy, and four refused. Of the 210 patients tested, 28 had MSI-H tumors. Similar numbers of MSI-H were captured, 14.8% preoperatively and 11% postoperatively. Overall, 88% of the high-risk group had tests, and the protocol caught 11% of MSI-H tumors that would have otherwise been missed. An estimated 3% of colon cancers can be attributed to Lynch syndrome. At least 80% of people with Lynch syndrome develop colorectal cancer, many of them before the age of 50.

MSI is a key factor in several cancers including colorectal, endometrial, ovarian, and gastric cancers. Colorectal cancer studies have demonstrated two mechanisms for MSI occurrence. In both cases, microsatellite insertions and deletions within tumor suppressor gene coding regions result in uncontrolled cell division and tumor growth. As a result of this testing, cancer may be caught earlier and physicians may be more proactive in treatment. The testing should be done before surgery, because a diagnosis may change the course of treatment. Testing after surgery also is beneficial as the knowledge gleaned can affect future care for patients and their families. The study was presented at the American Society of Colon and Rectal Surgeons Annual Scientific Meeting, held May 14-18, 2011, in Vancouver (BC, Canada).

Related Links:
Mayo Clinic




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.